EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer

Elisabetta Perrone iD, Alessandro Giordano, Maria Lucia Calcagni, Lucia Leccisotti iD, Roberto Moretti, Aleksandr Eismant iD, Kriti Ghai iD, Tanay Parkar iD, Aditi Mishra, Axel Heidenreich, Ralph M Wirtz, Jörg Müller iD und 2 weitere

Cancers · 26.01.2025 · 17 (3) · 405

DOI: 10.3390/cancers17030405 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 26.01.2025. Verfasst von Elisabetta Perrone und 13 weiteren Autor:innen. Beteiligte Einrichtung: CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aims to retrospectively assess the safety of [225Ac]Ac-PSMA-PRLT, both as monotherapy and in combination (TANDEM) with Lutetium-177, concerning tolerance after the radiopharmaceutical administration and long-term safety, its impact on salivary glands’ function, overall survival (OS), and follow-up duration. Between December 2020 and September 2024, 89 patients received a total of 151 cycles of [225Ac]Ac-PSMA-PRLT. Patients with at least one follow-up (n = 71) were included in the analysis to evaluate xerostomia, as well as long-term hematological, renal, and hepatic toxicities, graded according to CTCAE v5.0. The most common adverse event after the radiopharmaceutical administration was flare pain (n = 16). As of the time of analysis, 68 patients had passed away (76.4%; range of survival 5 days to 39 months, median 7 months), while 21 patients were still alive (23.6%; follow-up duration: 1–33 months). Severe (G3/G4) long-term adverse events were rare, with 15 cases of G3 anemia (21.1%), 6 cases of G3 leukocytopenia (8.4%), and 14 cases of G3/G4 thrombocytopenia (19.7%). Hematological toxicity was primarily associated with severe bone marrow involvement or prior chemotherapy. Additionally, one case of G3 nephrotoxicity (1.4%) and six cases of G3 hepatotoxicity (8.4%) were observed. Only nine patients (12.7%) reported de novo xerostomia (G1/G2). In conclusion, this study demonstrates that [225Ac]Ac-PSMA PRLT, both as monotherapy and combined with [177Lu]Lu-PSMA as TANDEM PRLT, is generally safe in terms of both tolerance after the radiopharmaceutical administration and long-term toxicity.

Schlagwörter

Stichwörter der Autor:innen

Actinium-225PSMAPSMA Radioligand Therapy (PRLT)TANDEM PRLTprostate cancersafetysurvival

Autor:innen und Institutionen

  • CURANOSTICUM Wiesbaden-Frankfurt, Center for Advanced Radiomolecular Precision Oncology, 65191 Wiesbaden, Germany.
  • Institute of Nuclear Medicine, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
  • Unit of Nuclear Medicine, Department of Diagnostic Imaging, Radiation Oncology and Hematology, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Unità della Fisica per le Scienze della Vita, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Rome, Italy.
  • Department of Urology, Uro-Oncology, Robot-Assisted and Reconstructive Surgery, Faculty of Medicine, University of Cologne, University Hospital Cologne, 50937 Cologne, Germany.
  • Institute of Pathology, St. Elisabeth Hospital Köln-Hohenlind, 50935 Cologne, Germany.

ORCID-Profile: Elisabetta Perrone, Lucia Leccisotti, Aleksandr Eismant, Kriti Ghai, Tanay Parkar, Jörg Müller, Richard P Baum

Zitieren

APA

Perrone, E., Giordano, A., Calcagni, M. L., Leccisotti, L., Moretti, R., Eismant, A., Ghai, K., Parkar, T., Mishra, A., Heidenreich, A., Wirtz, R. M., Müller, J., Greifenstein, L., & Baum, R. P. (2025). Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer. Cancers, 17(3), 405. https://doi.org/10.3390/cancers17030405

Vancouver

Perrone E, Giordano A, Calcagni ML, Leccisotti L, Moretti R, Eismant A, et al. Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer. Cancers. 2025;17(3):405. doi:10.3390/cancers17030405

BibTeX
@article{Perrone2025,
  author = {Perrone, Elisabetta and Giordano, Alessandro and Calcagni, Maria Lucia and Leccisotti, Lucia and Moretti, Roberto and Eismant, Aleksandr and Ghai, Kriti and Parkar, Tanay and Mishra, Aditi and Heidenreich, Axel and Wirtz, Ralph M and Müller, Jörg and Greifenstein, Lukas and Baum, Richard P},
  title = {Long-Term Safety and Survival Outcomes of [225Ac]Ac-PSMA (Prostate-Specific Membrane Antigen) and [225Ac]Ac-/[177Lu]Lu-PSMA (TANDEM) Radioligand Therapy (PRLT) in Metastatic Castration-Resistant Prostate Cancer},
  journal = {Cancers},
  year = {2025},
  volume = {17},
  number = {3},
  pages = {405},
  doi = {10.3390/cancers17030405}
}
Kostenlos starten →